6:17 PM
 | 
Jul 28, 2008
 |  BC Extra  |  Top Story

Amgen beats Street, gains on data

Amgen (NASDAQ:AMGN) reported 2Q08 adjusted diluted EPS of $1.14, beating by $0.12 the Street's estimate of $1.02 and up 2% from $1.12 in 2Q07. Second quarter revenues were up 1% to $3.8 billion from $3.7 billion in 2Q07. The Street was expecting $3.6 billion. Amgen, which reported earnings after market close, was up $6.56 (12%) to $60.48 on Monday. The stock move came after the company reported late Friday that denosumab...

Read the full 341 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >